Biogen ( NASDAQ:BIIB ) has received a significant boost with the Food and Drug Administration's accelerated approval for Qalsody, a drug aimed at treating ALS, a debilitating muscle-wasting disease. While the approval marks a significant milestone in Biogen's efforts to address critical medical needs, the company faces challenges amidst concerns over its earnings...
Looking at the options chain today, i would buy the $255 calls with
2022-9-16 expiration date for about
$3.40 premium.
Looking forward to read your opinion about it.
